Guangxi Wuzhou Zhongheng Group (SHA:600252) received approval from China's National Medical Products Administration to amend some information of its drug, clindamycin phosphate injection, after it passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange filing on Saturday.
Some of the changes included amending the modification to the drug formula and its manufacturing process and revising the drug quality standards.
The drug is mainly used to treat serious infections caused by sensitive anaerobic bacteria, streptococci, pneumococci, staphylococci, and other designated sensitive microorganisms, the Chinese drugmaker said.
The company's shares closed less than 3% higher.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。